Envestnet Asset Management Inc. Cuts Position in Medpace Holdings, Inc. $MEDP

Key Points

• Envestnet Asset Management cut its Medpace position by 30.2% in the second quarter, selling 40,222 shares and retaining 92,802 shares valued at approximately $49.1 million. Institutional investors and hedge funds collectively own 77.98% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 in EPS and $707.33 million in revenue, while revenue increased 17.2% year over year. The company guided to fiscal 2026 EPS of $17.25–$17.95.
• Analysts maintain a consensus “Hold” rating with an average price target of $595.20, below the stock’s $618.88 opening price. Company insiders have also sold $176.1 million worth of shares over the past three months.

Envestnet Asset Management Inc. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 30.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,802 shares of the company's stock after selling 40,222 shares during the period. Envestnet Asset Management Inc. owned approximately 0.33% of Medpace worth $49,147,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Medpace during the 2nd quarter worth approximately $1,323,047,000. Wasatch Advisors LP lifted its position in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock valued at $371,634,000 after acquiring an additional 125,625 shares during the period. State Street Corp lifted its position in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company's stock valued at $376,483,000 after acquiring an additional 28,666 shares during the period. Geode Capital Management LLC boosted its stake in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after acquiring an additional 38,760 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MEDP has been the subject of several research analyst reports. Leerink Partners set a $620.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Finally, Royal Bank Of Canada increased their price target on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $595.20.

Medpace Stock Performance

Medpace stock opened at $618.88 on Monday. The stock has a market cap of $17.27 billion, a PE ratio of 36.28, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The firm's 50-day simple moving average is $594.65 and its 200 day simple moving average is $516.25. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, Director Robert Kraft sold 3,858 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the sale, the director directly owned 955 shares in the company, valued at $590,008.55. The trade was a 80.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO August Troendle sold 27,833 shares of the company's stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $621.33, for a total transaction of $17,293,477.89. Following the sale, the chief executive officer owned 389,456 shares in the company, valued at $241,980,696.48. The trade was a 6.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 284,909 shares of company stock valued at $176,097,458 over the last three months. Company insiders own 20.50% of the company's stock.

Medpace Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.